Agenus Inc. (AGEN)
After hours:
| Previous Close | 11.47 |
| Open | 11.54 |
| Bid | 11.73 x 300 |
| Ask | 11.84 x 300 |
| Day's Range | 11.50 - 12.45 |
| 52 Week Range | 4.78 - 42.60 |
| Volume | |
| Avg. Volume | 814,793 |
| Market Cap | 246.112M |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Agenus Reports First Quarter 2024 Results
LEXINGTON, Mass., May 07, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the first quarter 2024. In a concurrent press release accompanying Agenus’ earnings announcement, a $100M royalty financing agreement between Ligand and Agenus was reported. This pivotal, minimally dilutive capital infusion will support the key development and launch readiness initiatives needed to advance t
- Business Wire
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
JUPITER, Fla. and LEXINGTON, Mass., May 07, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the companies have entered into a royalty financing agreement to support Agenus’ key development initiatives in the ongoing BOT/BAL clinical development program, including its planned confirmatory Phase 3 trial in its lead indication of patients with met
- Business Wire
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
LEXINGTON, Mass., May 01, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immunology-based therapies for cancer, received notice from NASDAQ on April 30, 2024, that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2). Accordingly, the Company now satisfies all requirements for continued listing on the NASDAQ Capital Market and the matter is now closed.
